Takeda Pharmaceutical Co. TAK
18.86
0.27
1.45%
as of 25 Sep
- Market cap
- $59.2B
- P/E
- 28.4×
Follow TAK
| Older periods | Jun '25 | Sep '25 | Dec '25 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
4.39% | 0.00% | 0.00% | 4.42% | |
| 2.13% | 0.00% | 0.00% | 2.15% | ||
ROIC |
2.42% | 0.00% | 0.00% | 2.88% | |
Return on Tangible Assets |
13.48% | 0.00% | 0.00% | 13.40% | |
Average Days of Receivables |
57.31 | 0.00 | 0.00 | 73.31 | |
Free Cash Flow per Share |
2.02 | 0.00 | 0.00 | 2.35 | |
Free Cash Flow |
6,324.44 | 8,314.41 | 10,878.22 | 7,420.86 | |
Capital Expenditures |
(3,696.62) | (3,167.12) | (4,954.63) | (3,704.87) | |
Piotroski F-Score |
6.00 | — | — | 6.00 | |
| Other line items | |||||
Cash ROIC |
12.32% | 13.49% | 18.37% | 13.56% | |
Accounts Receivable Turnover |
6.29 | 0.00 | 0.00 | 5.52 | |
Accounts Payable Turnover |
3.07 | 0.00 | 0.00 | 3.50 | |
Inventory Turnover |
1.21 | 0.00 | 0.00 | 1.18 | |
Average Days of Payables |
103.42 | 0.00 | 0.00 | 100.31 | |
Days of Inventory on Hand |
304.55 | 0.00 | 0.00 | 324.95 | |
Tax Rate |
0.10 | — | — | (0.17) | |
Research and Development Expense of Revenue |
15.57% | — | — | 14.77% | |
Selling, General and Administrative Expense of Revenue |
24.14% | — | — | 23.99% | |
Share Based Compensation of Revenue |
2.43% | 0.00% | 0.00% | 2.33% | |
Interest Coverage |
0.00 | — | — | 0.00 | |
Operating CF/Net income |
4.68 | 0.00 | 0.00 | 5.21 | |
Depreciation/Fixed assets |
0.56 | 0.56 | 0.73 | 0.53 | |
Capex/Depreciation |
(0.49) | (0.42) | (0.50) | (0.52) | |
Revenue per Share |
9.54 | — | — | 9.49 | |
Operating CF per Share |
3.20 | 0.00 | 0.00 | 3.52 | |
Capex per Share |
(1.18) | 0.00 | 0.00 | (1.17) | |
Capex to Sales |
0.12 | 0.00 | 0.00 | 0.12 | |
Net Profit Margin |
7.17% | — | — | 7.12% |
Columns are period end dates